FDA Turns Down Sensor-Embedded Tablet For Monitoring Medication Adherence
Executive Summary
The agency says it needs more information, and especially more usability testing, before it can approve a new drug application on a combination product that integrates Otsuka’s Abilify antipsychotic with an ingestible sensor made by Proteus, intended to improve medication adherence.
You may also be interested in...
First ‘Digital Medicine’ Approved, Slow Rollout Planned
FDA has approved Abilify MyCite, a treatment for some psychiatric conditions that integrates a drug with a sensor that records when the medication is taken. The goal is to track medication compliance. It is an important regulatory milestone for the nascent field of digital medicine, but many questions about the market remain.
FDA Guidance Sheds Light On Human Factor Studies For Combo Products
Questions from companies and FDA reviewers about human factor design and data requirements for combination products continue to grow. In response, the agency has issued a draft guidance.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.